{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:34:31Z","timestamp":1794710071255,"version":"4.9.1"},"reference-count":291,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1038\/s41582-022-00681-2","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T13:02:42Z","timestamp":1656075762000},"page":"476-495","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":402,"title":["The microbiome\u2013gut\u2013brain axis in Parkinson disease \u2014 from basic research to the clinic"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2979-3839","authenticated-orcid":false,"given":"Ai Huey","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen Yang","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony E.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"key":"681_CR1","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S1474-4422(19)30195-4","volume":"18","author":"SY Lim","year":"2019","unstructured":"Lim, S. Y. et al. Parkinson\u2019s disease in the Western Pacific region. Lancet Neurol. 18, 865\u2013879 (2019).","journal-title":"Lancet Neurol."},{"key":"681_CR2","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem, B. R., Okun, M. S. & Klein, C. Parkinson\u2019s disease. Lancet 397, 2284\u20132303 (2021).","journal-title":"Lancet"},{"key":"681_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11940-018-0539-9","volume":"20","author":"RF Pfeiffer","year":"2018","unstructured":"Pfeiffer, R. F. Gastrointestinal dysfunction in Parkinson\u2019s disease. Curr. Treat. Options Neurol. 20, 54 (2018).","journal-title":"Curr. Treat. Options Neurol."},{"key":"681_CR4","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1056\/NEJMra1600266","volume":"375","author":"SV Lynch","year":"2016","unstructured":"Lynch, S. V. & Pedersen, O. The human intestinal microbiome in health and disease. N. Engl. J. Med. 375, 2369\u20132379 (2016).","journal-title":"N. Engl. J. Med."},{"key":"681_CR5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S1474-4422(19)30356-4","volume":"19","author":"JF Cryan","year":"2020","unstructured":"Cryan, J. F., O\u2019Riordan, K. J., Sandhu, K., Peterson, V. & Dinan, T. G. The gut microbiome in neurological disorders. Lancet Neurol. 19, 179\u2013194 (2020).","journal-title":"Lancet Neurol."},{"key":"681_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.chom.2020.06.008","volume":"28","author":"P Fang","year":"2020","unstructured":"Fang, P., Kazmi, S. A., Jameson, K. G. & Hsiao, E. Y. The microbiome as a modifier of neurodegenerative disease risk. Cell Host Microbe 28, 201\u2013222 (2020).","journal-title":"Cell Host Microbe"},{"key":"681_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/d41586-021-00260-3","volume":"590","author":"C Willyard","year":"2021","unstructured":"Willyard, C. How gut microbes could drive brain disorders. Nature 590, 22\u201325 (2021).","journal-title":"Nature"},{"key":"681_CR8","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/ana.25982","volume":"89","author":"AH Tan","year":"2021","unstructured":"Tan, A. H. et al. Gut microbial ecosystem in Parkinson disease: new clinicobiological insights from multi-omics. Ann. Neurol. 89, 546\u2013559 (2021).","journal-title":"Ann. Neurol."},{"key":"681_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/BF00687767","volume":"76","author":"K Wakabayashi","year":"1988","unstructured":"Wakabayashi, K., Takahashi, H., Takeda, S., Ohama, E. & Ikuta, F. Parkinson\u2019s disease: the presence of Lewy bodies in Auerbach\u2019s and Meissner\u2019s plexuses. Acta Neuropathol. 76, 217\u2013221 (1988).","journal-title":"Acta Neuropathol."},{"key":"681_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging 24, 197\u2013211 (2003).","journal-title":"Neurobiol. Aging"},{"key":"681_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/mds.27556","volume":"34","author":"DP Breen","year":"2019","unstructured":"Breen, D. P., Halliday, G. M. & Lang, A. E. Gut-brain axis and the spread of \u03b1-synuclein pathology: vagal highway or dead end? Mov. Disord. 34, 307\u2013316 (2019).","journal-title":"Mov. Disord."},{"key":"681_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/nrneurol.2015.197","volume":"11","author":"L Klingelhoefer","year":"2015","unstructured":"Klingelhoefer, L. & Reichmann, H. Pathogenesis of Parkinson disease \u2014 the gut-brain axis and environmental factors. Nat. Rev. Neurol. 11, 625\u2013636 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"681_CR13","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1093\/brain\/awaa238","volume":"143","author":"J Horsager","year":"2020","unstructured":"Horsager, J. et al. Brain-first versus body-first Parkinson\u2019s disease: a multimodal imaging case-control study. Brain 143, 3077\u20133088 (2020).","journal-title":"Brain"},{"key":"681_CR14","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/jnnp-2015-311680","volume":"87","author":"KL Adams-Carr","year":"2016","unstructured":"Adams-Carr, K. L. et al. Constipation preceding Parkinson\u2019s disease: a systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry 87, 710\u2013716 (2016).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"681_CR15","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1002\/mds.28636","volume":"36","author":"GD Scott","year":"2021","unstructured":"Scott, G. D., Lim, M. M., Drake, M. G., Woltjer, R. & Quinn, J. F. Onset of skin, gut, and genitourinary prodromal Parkinson\u2019s disease: a study of 1.5 million veterans. Mov. Disord. 36, 2094\u20132103 (2021).","journal-title":"Mov. Disord."},{"key":"681_CR16","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1212\/WNL.0000000000003961","volume":"88","author":"B Liu","year":"2017","unstructured":"Liu, B. et al. Vagotomy and Parkinson disease: a Swedish register-based matched-cohort study. Neurology 88, 1996\u20132002 (2017).","journal-title":"Neurology"},{"key":"681_CR17","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/ana.24448","volume":"78","author":"E Svensson","year":"2015","unstructured":"Svensson, E. et al. Vagotomy and subsequent risk of Parkinson\u2019s disease. Ann. Neurol. 78, 522\u2013529 (2015).","journal-title":"Ann. Neurol."},{"key":"681_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.tins.2016.10.008","volume":"40","author":"S Engelender","year":"2017","unstructured":"Engelender, S. & Isacson, O. The threshold theory for Parkinson\u2019s disease. Trends Neurosci. 40, 4\u201314 (2017).","journal-title":"Trends Neurosci."},{"key":"681_CR19","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/ana.24531","volume":"78","author":"OB Tysnes","year":"2015","unstructured":"Tysnes, O. B. et al. Does vagotomy reduce the risk of Parkinson\u2019s disease? Ann. Neurol. 78, 1011\u20131012 (2015).","journal-title":"Ann. Neurol."},{"key":"681_CR20","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S1474-4422(18)30162-5","volume":"17","author":"K Knudsen","year":"2018","unstructured":"Knudsen, K. et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurol. 17, 618\u2013628 (2018).","journal-title":"Lancet Neurol."},{"key":"681_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00401-013-1214-6","volume":"127","author":"D Hilton","year":"2014","unstructured":"Hilton, D. et al. Accumulation of \u03b1-synuclein in the bowel of patients in the pre-clinical phase of Parkinson\u2019s disease. Acta Neuropathol. 127, 235\u2013241 (2014).","journal-title":"Acta Neuropathol."},{"key":"681_CR22","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/mds.25020","volume":"27","author":"KM Shannon","year":"2012","unstructured":"Shannon, K. M., Keshavarzian, A., Dodiya, H. B., Jakate, S. & Kordower, J. H. Is alpha-synuclein in the colon a biomarker for premotor Parkinson\u2019s disease? Evidence from 3 cases. Mov. Disord. 27, 716\u2013719 (2012).","journal-title":"Mov. Disord."},{"key":"681_CR23","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/ana.24648","volume":"79","author":"MG Stokholm","year":"2016","unstructured":"Stokholm, M. G., Danielsen, E. H., Hamilton-Dutoit, S. J. & Borghammer, P. Pathological \u03b1-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann. Neurol. 79, 940\u2013949 (2016).","journal-title":"Ann. Neurol."},{"key":"681_CR24","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00401-010-0664-3","volume":"119","author":"TG Beach","year":"2010","unstructured":"Beach, T. G. et al. Multi-organ distribution of phosphorylated \u03b1-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 119, 689\u2013702 (2010).","journal-title":"Acta Neuropathol."},{"key":"681_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00401-020-02233-8","volume":"141","author":"ZI Tanei","year":"2021","unstructured":"Tanei, Z. I. et al. Lewy pathology of the esophagus correlates with the progression of Lewy body disease: a Japanese cohort study of autopsy cases. Acta Neuropathol. 141, 25\u201337 (2021).","journal-title":"Acta Neuropathol."},{"key":"681_CR26","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.3233\/JPD-212733","volume":"11","author":"TG Beach","year":"2021","unstructured":"Beach, T. G. et al. Vagus nerve and stomach synucleinopathy in Parkinson\u2019s disease, incidental Lewy body disease, and normal elderly subjects: evidence against the \u201cbody-first\u201d hypothesis. J. Parkinsons Dis. 11, 1833\u20131843 (2021).","journal-title":"J. Parkinsons Dis."},{"key":"681_CR27","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00401-019-02040-w","volume":"138","author":"N Van Den Berge","year":"2019","unstructured":"Van Den Berge, N. et al. Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats. Acta Neuropathol. 138, 535\u2013550 (2019).","journal-title":"Acta Neuropathol."},{"key":"681_CR28","doi-asserted-by":"publisher","first-page":"S345","DOI":"10.3233\/JPD-191703","volume":"9","author":"B Killinger","year":"2019","unstructured":"Killinger, B. & Labrie, V. The appendix in Parkinson\u2019s disease: from vestigial remnant to vital organ? J. Parkinsons Dis. 9, S345\u2013S358 (2019).","journal-title":"J. Parkinsons Dis."},{"key":"681_CR29","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1002\/mds.27794","volume":"34","author":"K Tsukita","year":"2019","unstructured":"Tsukita, K., Sakamaki-Tsukita, H., Tanaka, K., Suenaga, T. & Takahashi, R. Value of in vivo \u03b1-synuclein deposits in Parkinson\u2019s disease: a systematic review and meta-analysis. Mov. Disord. 34, 1452\u20131463 (2019).","journal-title":"Mov. Disord."},{"key":"681_CR30","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00401-012-1040-2","volume":"124","author":"DM Annerino","year":"2012","unstructured":"Annerino, D. M. et al. Parkinson\u2019s disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta Neuropathol. 124, 665\u2013680 (2012).","journal-title":"Acta Neuropathol."},{"key":"681_CR31","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00401-014-1343-6","volume":"128","author":"S Holmqvist","year":"2014","unstructured":"Holmqvist, S. et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. 128, 805\u2013820 (2014).","journal-title":"Acta Neuropathol."},{"key":"681_CR32","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","volume":"103","author":"S Kim","year":"2019","unstructured":"Kim, S. et al. Transneuronal propagation of pathologic \u03b1-synuclein from the gut to the brain models Parkinson\u2019s disease. Neuron 103, 627\u2013641 (2019).","journal-title":"Neuron"},{"key":"681_CR33","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41593-020-0589-7","volume":"23","author":"C Challis","year":"2020","unstructured":"Challis, C. et al. Gut-seeded \u03b1-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice. Nat. Neurosci. 23, 327\u2013336 (2020).","journal-title":"Nat. Neurosci."},{"key":"681_CR34","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/brain\/awab061","volume":"144","author":"N Van Den Berge","year":"2021","unstructured":"Van Den Berge, N. et al. Ageing promotes pathological alpha-synuclein propagation and autonomic dysfunction in wild-type rats. Brain 144, 1853\u20131868 (2021).","journal-title":"Brain"},{"key":"681_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40035-019-0146-z","volume":"8","author":"L Rota","year":"2019","unstructured":"Rota, L. et al. Constipation, deficit in colon contractions and alpha-synuclein inclusions within the colon precede motor abnormalities and neurodegeneration in the central nervous system in a mouse model of alpha-synucleinopathy. Transl. Neurodegener. 8, 5 (2019).","journal-title":"Transl. Neurodegener."},{"key":"681_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13024-021-00439-2","volume":"16","author":"M Gries","year":"2021","unstructured":"Gries, M. et al. Parkinson mice show functional and molecular changes in the gut long before motoric disease onset. Mol. Neurodegener. 16, 34 (2021).","journal-title":"Mol. Neurodegener."},{"key":"681_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/srep34477","volume":"6","author":"SG Chen","year":"2016","unstructured":"Chen, S. G. et al. Exposure to the functional bacterial amyloid protein curli enhances alpha-synuclein aggregation in aged fischer 344 rats and Caenorhabditis elegans. Sci. Rep. 6, 34477 (2016).","journal-title":"Sci. Rep."},{"key":"681_CR38","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.53111","volume":"9","author":"TR Sampson","year":"2020","unstructured":"Sampson, T. R. et al. A gut bacterial amyloid promotes \u03b1-synuclein aggregation and motor impairment in mice. Elife 9, e53111 (2020).","journal-title":"Elife"},{"key":"681_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.13777","volume":"32","author":"L Leclair-Visonneau","year":"2020","unstructured":"Leclair-Visonneau, L., Neunlist, M., Derkinderen, P. & Lebouvier, T. The gut in Parkinson\u2019s disease: bottom-up, top-down, or neither? Neurogastroenterol. Motil. 32, e13777 (2020).","journal-title":"Neurogastroenterol. Motil."},{"key":"681_CR40","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00401-016-1661-y","volume":"133","author":"A Ulusoy","year":"2017","unstructured":"Ulusoy, A. et al. Brain-to-stomach transfer of \u03b1-synuclein via vagal preganglionic projections. Acta Neuropathol. 133, 381\u2013393 (2017).","journal-title":"Acta Neuropathol."},{"key":"681_CR41","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1136\/gutjnl-2012-302550","volume":"62","author":"G Matteoli","year":"2013","unstructured":"Matteoli, G. & Boeckxstaens, G. E. The vagal innervation of the gut and immune homeostasis. Gut 62, 1214\u20131222 (2013).","journal-title":"Gut"},{"key":"681_CR42","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/brain\/awaa096","volume":"143","author":"ML Arotcarena","year":"2020","unstructured":"Arotcarena, M. L. et al. Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. Brain 143, 1462\u20131475 (2020).","journal-title":"Brain"},{"key":"681_CR43","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41380-019-0608-9","volume":"26","author":"WL Kuan","year":"2021","unstructured":"Kuan, W. L. et al. Systemic \u03b1-synuclein injection triggers selective neuronal pathology as seen in patients with Parkinson\u2019s disease. Mol. Psychiatry 26, 556\u2013567 (2021).","journal-title":"Mol. Psychiatry"},{"key":"681_CR44","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12974-016-0608-5","volume":"13","author":"C Pellegrini","year":"2016","unstructured":"Pellegrini, C. et al. Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. J. Neuroinflamm. 13, 146 (2016).","journal-title":"J. Neuroinflamm."},{"key":"681_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.13726","volume":"32","author":"SM O\u2019Donovan","year":"2020","unstructured":"O\u2019Donovan, S. M. et al. Nigral overexpression of \u03b1-synuclein in a rat Parkinson\u2019s disease model indicates alterations in the enteric nervous system and the gut microbiome. Neurogastroenterol. Motil. 32, e13726 (2020).","journal-title":"Neurogastroenterol. Motil."},{"key":"681_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-017-1777-8","volume":"135","author":"A Lionnet","year":"2018","unstructured":"Lionnet, A. et al. Does Parkinson\u2019s disease start in the gut? Acta Neuropathol. 135, 1\u201312 (2018).","journal-title":"Acta Neuropathol."},{"key":"681_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028032","volume":"6","author":"CB Forsyth","year":"2011","unstructured":"Forsyth, C. B. et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson\u2019s disease. PLoS ONE 6, e28032 (2011).","journal-title":"PLoS ONE"},{"key":"681_CR48","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/mds.25736","volume":"29","author":"LP Kelly","year":"2014","unstructured":"Kelly, L. P. et al. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson\u2019s disease. Mov. Disord. 29, 999\u20131009 (2014).","journal-title":"Mov. Disord."},{"key":"681_CR49","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40478-015-0196-0","volume":"3","author":"T Clairembault","year":"2015","unstructured":"Clairembault, T. et al. Structural alterations of the intestinal epithelial barrier in Parkinson\u2019s disease. Acta Neuropathol. Commun. 3, 12 (2015).","journal-title":"Acta Neuropathol. Commun."},{"key":"681_CR50","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1002\/mds.27326","volume":"33","author":"MC Houser","year":"2018","unstructured":"Houser, M. C. et al. Stool immune profiles evince gastrointestinal inflammation in Parkinson\u2019s disease. Mov. Disord. 33, 793\u2013804 (2018).","journal-title":"Mov. Disord."},{"key":"681_CR51","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.parkreldis.2018.02.022","volume":"50","author":"A Schwiertz","year":"2018","unstructured":"Schwiertz, A. et al. Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 50, 104\u2013107 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"681_CR52","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1136\/gutjnl-2018-316844","volume":"68","author":"P Perez-Pardo","year":"2019","unstructured":"Perez-Pardo, P. et al. Role of TLR4 in the gut-brain axis in Parkinson\u2019s disease: a translational study from men to mice. Gut 68, 829\u2013843 (2019).","journal-title":"Gut"},{"key":"681_CR53","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41575-019-0261-4","volume":"17","author":"JF Burgueno","year":"2020","unstructured":"Burgueno, J. F. & Abreu, M. T. Epithelial Toll-like receptors and their role in gut homeostasis and disease. Nat. Rev. Gastroenterol. Hepatol. 17, 263\u2013278 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"681_CR54","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bbi.2019.06.042","volume":"81","author":"A Kouli","year":"2019","unstructured":"Kouli, A., Horne, C. B. & Williams-Gray, C. H. Toll-like receptors and their therapeutic potential in Parkinson\u2019s disease and \u03b1-synucleinopathies. Brain Behav. Immun. 81, 41\u201351 (2019).","journal-title":"Brain Behav. Immun."},{"key":"681_CR55","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.nbd.2012.09.007","volume":"50","author":"D Devos","year":"2013","unstructured":"Devos, D. et al. Colonic inflammation in Parkinson\u2019s disease. Neurobiol. Dis. 50, 42\u201348 (2013).","journal-title":"Neurobiol. Dis."},{"key":"681_CR56","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/jnc.12742","volume":"130","author":"T Clairembault","year":"2014","unstructured":"Clairembault, T. et al. Enteric GFAP expression and phosphorylation in Parkinson\u2019s disease. J. Neurochem. 130, 805\u2013815 (2014).","journal-title":"J. Neurochem."},{"key":"681_CR57","doi-asserted-by":"publisher","first-page":"9199","DOI":"10.3390\/ijms21239199","volume":"21","author":"L Benvenuti","year":"2020","unstructured":"Benvenuti, L. et al. Enteric glia at the crossroads between intestinal immune system and epithelial barrier: implications for Parkinson disease. Int. J. Mol. Sci. 21, 9199 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"681_CR58","doi-asserted-by":"publisher","DOI":"10.14802\/jmd.21085","author":"JW Hor","year":"2021","unstructured":"Hor, J. W. et al. Fecal calprotectin in Parkinson\u2019s disease and multiple system atrophy. J. Mov. Disord. https:\/\/doi.org\/10.14802\/jmd.21085 (2021).","journal-title":"J. Mov. Disord."},{"key":"681_CR59","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/s41582-020-0344-4","volume":"16","author":"EK Tan","year":"2020","unstructured":"Tan, E. K. et al. Parkinson disease and the immune system \u2014 associations, mechanisms and therapeutics. Nat. Rev. Neurol. 16, 303\u2013318 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"681_CR60","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41531-016-0002-0","volume":"3","author":"MC Houser","year":"2017","unstructured":"Houser, M. C. & Tansey, M. G. The gut-brain axis: is intestinal inflammation a silent driver of Parkinson\u2019s disease pathogenesis? NPJ Parkinsons Dis. 3, 3 (2017).","journal-title":"NPJ Parkinsons Dis."},{"key":"681_CR61","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1159\/000477990","volume":"9","author":"EB Stolzenberg","year":"2017","unstructured":"Stolzenberg, E. B. et al. Role for neuronal alpha-synuclein in gastrointestinal immunity. J. Innate Immun. 9, 456\u2013463 (2017).","journal-title":"J. Innate Immun."},{"key":"681_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JPD-140491","volume":"5","author":"HE Allen Reish","year":"2015","unstructured":"Allen Reish, H. E. & Standaert, D. G. Role of \u03b1-synuclein in inducing innate and adaptive immunity in Parkinson disease. J. Parkinsons Dis. 5, 1\u201319 (2015).","journal-title":"J. Parkinsons Dis."},{"key":"681_CR63","doi-asserted-by":"publisher","first-page":"9587","DOI":"10.1073\/pnas.1610099113","volume":"113","author":"W Wang","year":"2016","unstructured":"Wang, W. et al. Caspase-1 causes truncation and aggregation of the Parkinson\u2019s disease-associated protein \u03b1-synuclein. Proc. Natl Acad. Sci. USA 113, 9587\u20139592 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"681_CR64","first-page":"13","volume":"2","author":"S Grathwohl","year":"2021","unstructured":"Grathwohl, S. et al. Specific immune modulation of experimental colitis drives enteric alpha-synuclein accumulation and triggers age-related Parkinson-like brain pathology. Free Neuropathol. 2, 13 (2021).","journal-title":"Free Neuropathol."},{"key":"681_CR65","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/JIR.S196552","volume":"12","author":"H Resnikoff","year":"2019","unstructured":"Resnikoff, H. et al. Colonic inflammation affects myenteric alpha-synuclein in nonhuman primates. J. Inflamm. Res. 12, 113\u2013126 (2019).","journal-title":"J. Inflamm. Res."},{"key":"681_CR66","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/mds.23838","volume":"27","author":"KM Shannon","year":"2012","unstructured":"Shannon, K. M. et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson\u2019s disease. Mov. Disord. 27, 709\u2013715 (2012).","journal-title":"Mov. Disord."},{"key":"681_CR67","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00401-018-1943-7","volume":"137","author":"A Prigent","year":"2019","unstructured":"Prigent, A. et al. Enteric alpha-synuclein expression is increased in Crohn\u2019s disease. Acta Neuropathol. 137, 359\u2013361 (2019).","journal-title":"Acta Neuropathol."},{"key":"681_CR68","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.92295","volume":"2","author":"R Chandra","year":"2017","unstructured":"Chandra, R., Hiniker, A., Kuo, Y. M., Nussbaum, R. L. & Liddle, R. A. \u03b1-Synuclein in gut endocrine cells and its implications for Parkinson\u2019s disease. JCI Insight 2, e92295 (2017).","journal-title":"JCI Insight"},{"key":"681_CR69","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","volume":"167","author":"TR Sampson","year":"2016","unstructured":"Sampson, T. R. et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson\u2019s disease. Cell 167, 1469\u20131480 (2016).","journal-title":"Cell"},{"key":"681_CR70","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41586-019-1405-y","volume":"571","author":"D Matheoud","year":"2019","unstructured":"Matheoud, D. et al. Intestinal infection triggers Parkinson\u2019s disease-like symptoms in Pink1(-\/-) mice. Nature 571, 565\u2013569 (2019).","journal-title":"Nature"},{"key":"681_CR71","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.parkreldis.2016.08.019","volume":"32","author":"MM Unger","year":"2016","unstructured":"Unger, M. M. et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson\u2019s disease and age-matched controls. Parkinsonism Relat. Disord. 32, 66\u201372 (2016).","journal-title":"Parkinsonism Relat. Disord."},{"key":"681_CR72","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1007\/s00415-019-09321-0","volume":"267","author":"M Rolli-Derkinderen","year":"2020","unstructured":"Rolli-Derkinderen, M. et al. Is Parkinson\u2019s disease a chronic low-grade inflammatory bowel disease? J. Neurol. 267, 2207\u20132213 (2020).","journal-title":"J. Neurol."},{"key":"681_CR73","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/17474124.2017.1343143","volume":"11","author":"M Vancamelbeke","year":"2017","unstructured":"Vancamelbeke, M. & Vermeire, S. The intestinal barrier: a fundamental role in health and disease. Expert. Rev. Gastroenterol. Hepatol. 11, 821\u2013834 (2017).","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"681_CR74","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.tim.2017.11.002","volume":"26","author":"A Heintz-Buschart","year":"2018","unstructured":"Heintz-Buschart, A. & Wilmes, P. Human gut microbiome: function matters. Trends Microbiol. 26, 563\u2013574 (2018).","journal-title":"Trends Microbiol."},{"key":"681_CR75","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nri.2017.7","volume":"17","author":"M Levy","year":"2017","unstructured":"Levy, M., Kolodziejczyk, A. A., Thaiss, C. A. & Elinav, E. Dysbiosis and the immune system. Nat. Rev. Immunol. 17, 219\u2013232 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"681_CR76","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.cell.2019.12.025","volume":"180","author":"J Walter","year":"2020","unstructured":"Walter, J., Armet, A. M., Finlay, B. B. & Shanahan, F. Establishing or exaggerating causality for the gut microbiome: lessons from human microbiota-associated rodents. Cell 180, 221\u2013232 (2020).","journal-title":"Cell"},{"key":"681_CR77","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.cell.2018.02.044","volume":"172","author":"TSB Schmidt","year":"2018","unstructured":"Schmidt, T. S. B., Raes, J. & Bork, P. The human gut microbiome: from association to modulation. Cell 172, 1198\u20131215 (2018).","journal-title":"Cell"},{"key":"681_CR78","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature12820","volume":"505","author":"LA David","year":"2014","unstructured":"David, L. A. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559\u2013563 (2014).","journal-title":"Nature"},{"key":"681_CR79","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature11053","volume":"486","author":"T Yatsunenko","year":"2012","unstructured":"Yatsunenko, T. et al. Human gut microbiome viewed across age and geography. Nature 486, 222\u2013227 (2012).","journal-title":"Nature"},{"key":"681_CR80","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1126\/science.aad3503","volume":"352","author":"GJ Falony","year":"2020","unstructured":"Falony, G. J. et al. Population level analysis of gut microbiome variation. Science 352, 560\u2013564 (2020).","journal-title":"Science"},{"key":"681_CR81","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nature25979","volume":"555","author":"L Maier","year":"2018","unstructured":"Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623\u2013628 (2018).","journal-title":"Nature"},{"key":"681_CR82","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1053\/j.gastro.2020.09.057","volume":"160","author":"F Shanahan","year":"2021","unstructured":"Shanahan, F., Ghosh, T. S. & O\u2019Toole, P. W. The healthy microbiome \u2014 what is the definition of a healthy gut microbiome? Gastroenterology 160, 483\u2013494 (2021).","journal-title":"Gastroenterology"},{"key":"681_CR83","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.chom.2020.07.013","volume":"28","author":"EN DeJong","year":"2020","unstructured":"DeJong, E. N., Surette, M. G. & Bowdish, D. M. E. The gut microbiota and unhealthy aging: disentangling cause from consequence. Cell Host Microbe 28, 180\u2013189 (2020).","journal-title":"Cell Host Microbe"},{"key":"681_CR84","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.cell.2017.11.024","volume":"171","author":"P Kundu","year":"2017","unstructured":"Kundu, P., Blacher, E., Elinav, E. & Pettersson, S. Our gut microbiome: the evolving inner self. Cell 171, 1481\u20131493 (2017).","journal-title":"Cell"},{"key":"681_CR85","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nature11319","volume":"488","author":"MJ Claesson","year":"2012","unstructured":"Claesson, M. J. et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 488, 178\u2013184 (2012).","journal-title":"Nature"},{"key":"681_CR86","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41574-018-0059-4","volume":"14","author":"C Franceschi","year":"2018","unstructured":"Franceschi, C., Garagnani, P., Parini, P., Giuliani, C. & Santoro, A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat. Rev. Endocrinol. 14, 576\u2013590 (2018).","journal-title":"Nat. Rev. Endocrinol."},{"key":"681_CR87","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.chom.2017.03.002","volume":"21","author":"N Thevaranjan","year":"2017","unstructured":"Thevaranjan, N. et al. Age-associated microbial dysbiosis promotes intestinal permeability, systemic inflammation, and macrophage dysfunction. Cell Host Microbe 21, 455\u2013466 (2017).","journal-title":"Cell Host Microbe"},{"key":"681_CR88","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/ismej.2015.88","volume":"10","author":"IB Jeffery","year":"2016","unstructured":"Jeffery, I. B., Lynch, D. B. & O\u2019Toole, P. W. Composition and temporal stability of the gut microbiota in older persons. ISME J. 10, 170\u2013182 (2016).","journal-title":"ISME J."},{"key":"681_CR89","doi-asserted-by":"publisher","first-page":"R832","DOI":"10.1016\/j.cub.2016.08.015","volume":"26","author":"F Kong","year":"2016","unstructured":"Kong, F. et al. Gut microbiota signatures of longevity. Curr. Biol. 26, R832\u2013R833 (2016).","journal-title":"Curr. Biol."},{"key":"681_CR90","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.mad.2019.02.001","volume":"179","author":"N Tuikhar","year":"2019","unstructured":"Tuikhar, N. et al. Comparative analysis of the gut microbiota in centenarians and young adults shows a common signature across genotypically non-related populations. Mech. Ageing Dev. 179, 23\u201335 (2019).","journal-title":"Mech. Ageing Dev."},{"key":"681_CR91","doi-asserted-by":"publisher","first-page":"e00325-19","DOI":"10.1128\/mSystems.00325-19","volume":"4","author":"L Wu","year":"2019","unstructured":"Wu, L. et al. A cross-sectional study of compositional and functional profiles of gut microbiota in Sardinian centenarians. mSystems 4, e00325-19 (2019).","journal-title":"mSystems"},{"key":"681_CR92","doi-asserted-by":"publisher","first-page":"e00124-20","DOI":"10.1128\/mSystems.00124-20","volume":"5","author":"S Rampelli","year":"2020","unstructured":"Rampelli, S. et al. Shotgun metagenomics of gut microbiota in humans with up to extreme longevity and the increasing role of xenobiotic degradation. mSystems 5, e00124-20 (2020).","journal-title":"mSystems"},{"key":"681_CR93","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3233\/JPD-202237","volume":"11","author":"MS Cirstea","year":"2021","unstructured":"Cirstea, M. S. et al. The gut mycobiome in Parkinson\u2019s disease. J. Parkinsons Dis. 11, 153\u2013158 (2021).","journal-title":"J. Parkinsons Dis."},{"key":"681_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0428-y","volume":"9","author":"JR Bedarf","year":"2017","unstructured":"Bedarf, J. R. et al. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naive Parkinson\u2019s disease patients. Genome Med. 9, 39 (2017).","journal-title":"Genome Med."},{"key":"681_CR95","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/mds.26942","volume":"32","author":"EM Hill-Burns","year":"2017","unstructured":"Hill-Burns, E. M. et al. Parkinson\u2019s disease and Parkinson\u2019s disease medications have distinct signatures of the gut microbiome. Mov. Disord. 32, 739\u2013749 (2017).","journal-title":"Mov. Disord."},{"key":"681_CR96","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/mds.28052","volume":"35","author":"MS Cirstea","year":"2020","unstructured":"Cirstea, M. S. et al. Microbiota composition and metabolism are associated with gut function in Parkinson\u2019s disease. Mov. Disord. 35, 1208\u20131217 (2020).","journal-title":"Mov. Disord."},{"key":"681_CR97","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/mds.28119","volume":"35","author":"H Nishiwaki","year":"2020","unstructured":"Nishiwaki, H. et al. Meta-analysis of gut dysbiosis in Parkinson\u2019s disease. Mov. Disord. 35, 1626\u20131635 (2020).","journal-title":"Mov. Disord."},{"key":"681_CR98","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/mds.27581","volume":"34","author":"M Barichella","year":"2019","unstructured":"Barichella, M. et al. Unraveling gut microbiota in Parkinson\u2019s disease and atypical parkinsonism. Mov. Disord. 34, 396\u2013405 (2019).","journal-title":"Mov. Disord."},{"key":"681_CR99","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41531-021-00156-z","volume":"7","author":"S Romano","year":"2021","unstructured":"Romano, S. et al. Meta-analysis of the Parkinson\u2019s disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons Dis. 7, 27 (2021).","journal-title":"NPJ Parkinsons Dis."},{"key":"681_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.parkreldis.2021.11.017","volume":"94","author":"TS Toh","year":"2022","unstructured":"Toh, T. S. et al. Gut microbiome in Parkinson\u2019s disease: new insights from meta-analysis. Parkinsonism Relat. Disord. 94, 1\u20139 (2022).","journal-title":"Parkinsonism Relat. Disord."},{"key":"681_CR101","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-020-00775-7","volume":"18","author":"F Baldini","year":"2020","unstructured":"Baldini, F. et al. Parkinson\u2019s disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions. BMC Biol. 18, 62 (2020).","journal-title":"BMC Biol."},{"key":"681_CR102","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41531-020-0112-6","volume":"6","author":"ZD Wallen","year":"2020","unstructured":"Wallen, Z. D. et al. Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens. NPJ Parkinsons Dis. 6, 11 (2020).","journal-title":"NPJ Parkinsons Dis."},{"key":"681_CR103","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1093\/brain\/awaa201","volume":"143","author":"Y Qian","year":"2020","unstructured":"Qian, Y. et al. Gut metagenomics-derived genes as potential biomarkers of Parkinson\u2019s disease. Brain 143, 2474\u20132489 (2020).","journal-title":"Brain"},{"key":"681_CR104","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/jgh3.12450","volume":"5","author":"AH Tan","year":"2021","unstructured":"Tan, A. H., Hor, J. W., Chong, C. W. & Lim, S. Y. Probiotics for Parkinson\u2019s disease: current evidence and future directions. JGH Open. 5, 414\u2013419 (2021).","journal-title":"JGH Open."},{"key":"681_CR105","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1136\/gutjnl-2018-316723","volume":"67","author":"PD Cani","year":"2018","unstructured":"Cani, P. D. Human gut microbiome: hopes, threats and promises. Gut 67, 1716\u20131725 (2018).","journal-title":"Gut"},{"key":"681_CR106","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.parkreldis.2018.06.020","volume":"56","author":"AH Tan","year":"2018","unstructured":"Tan, A. H. et al. Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 56, 58\u201364 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"681_CR107","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.parkreldis.2020.06.015","volume":"77","author":"VW Yong","year":"2020","unstructured":"Yong, V. W. et al. Progressive and accelerated weight and body fat loss in Parkinson\u2019s disease: a three-year prospective longitudinal study. Parkinsonism Relat. Disord. 77, 28\u201335 (2020).","journal-title":"Parkinsonism Relat. Disord."},{"key":"681_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01973-8","volume":"8","author":"C Duvallet","year":"2017","unstructured":"Duvallet, C., Gibbons, S. M., Gurry, T., Irizarry, R. A. & Alm, E. J. Meta-analysis of gut microbiome studies identifies disease-specific and shared responses. Nat. Commun. 8, 1784 (2017).","journal-title":"Nat. Commun."},{"key":"681_CR109","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41587-020-0603-3","volume":"39","author":"A Almeida","year":"2021","unstructured":"Almeida, A. et al. A unified catalog of 204,938 reference genomes from the human gut microbiome. Nat. Biotechnol. 39, 105\u2013114 (2021).","journal-title":"Nat. Biotechnol."},{"key":"681_CR110","doi-asserted-by":"publisher","first-page":"e00561-20","DOI":"10.1128\/mSystems.00561-20","volume":"5","author":"S Vascellari","year":"2020","unstructured":"Vascellari, S. et al. Gut microbiota and metabolome alterations associated with Parkinson\u2019s disease. mSystems 5, e00561-20 (2020).","journal-title":"mSystems"},{"key":"681_CR111","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13024-021-00427-6","volume":"16","author":"VTE Aho","year":"2021","unstructured":"Aho, V. T. E. et al. Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson\u2019s disease. Mol. Neurodegener. 16, 6 (2021).","journal-title":"Mol. Neurodegener."},{"key":"681_CR112","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41575-019-0157-3","volume":"16","author":"B Dalile","year":"2019","unstructured":"Dalile, B., Van Oudenhove, L., Vervliet, B. & Verbeke, K. The role of short-chain fatty acids in microbiota-gut-brain communication. Nat. Rev. Gastroenterol. Hepatol. 16, 461\u2013478 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"681_CR113","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.bbr.2015.05.052","volume":"291","author":"S Sharma","year":"2015","unstructured":"Sharma, S., Taliyan, R. & Singh, S. Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: modulation of histone deacetylase activity. Behav. Brain Res. 291, 306\u2013314 (2015).","journal-title":"Behav. Brain Res."},{"key":"681_CR114","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1016\/j.neuropharm.2012.01.026","volume":"62","author":"P Rane","year":"2012","unstructured":"Rane, P. et al. The histone deacetylase inhibitor, sodium butyrate, alleviates cognitive deficits in pre-motor stage PD. Neuropharmacology 62, 2409\u20132412 (2012).","journal-title":"Neuropharmacology"},{"key":"681_CR115","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jnutbio.2019.03.021","volume":"69","author":"S Srivastav","year":"2019","unstructured":"Srivastav, S. et al. Probiotics mixture increases butyrate, and subsequently rescues the nigral dopaminergic neurons from MPTP and rotenone-induced neurotoxicity. J. Nutr. Biochem. 69, 73\u201386 (2019).","journal-title":"J. Nutr. Biochem."},{"key":"681_CR116","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/mds.27203","volume":"33","author":"AH Tan","year":"2018","unstructured":"Tan, A. H. et al. Altered gut microbiome and metabolome in patients with multiple system atrophy. Mov. Disord. 33, 174 (2018).","journal-title":"Mov. Disord."},{"key":"681_CR117","doi-asserted-by":"publisher","first-page":"108807","DOI":"10.1016\/j.celrep.2021.108807","volume":"34","author":"D Rosario","year":"2021","unstructured":"Rosario, D. et al. Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson\u2019s disease. Cell Rep. 34, 108807 (2021).","journal-title":"Cell Rep."},{"key":"681_CR118","doi-asserted-by":"publisher","first-page":"6915","DOI":"10.18632\/aging.102221","volume":"11","author":"Y Pu","year":"2019","unstructured":"Pu, Y. et al. Antibiotic-induced microbiome depletion protects against MPTP-induced dopaminergic neurotoxicity in the brain. Aging 11, 6915\u20136929 (2019).","journal-title":"Aging"},{"key":"681_CR119","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.neuro.2019.11.009","volume":"76","author":"W Xie","year":"2020","unstructured":"Xie, W. et al. Twice subacute MPTP administrations induced time-dependent dopaminergic neurodegeneration and inflammation in midbrain and ileum, as well as gut microbiota disorders in PD mice. Neurotoxicology 76, 200\u2013212 (2020).","journal-title":"Neurotoxicology"},{"key":"681_CR120","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1021\/acschemneuro.0c00475","volume":"11","author":"Y Zhu","year":"2020","unstructured":"Zhu, Y. et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced Parkinson\u2019s disease in mouse: potential association between neurotransmitter disturbance and gut microbiota dysbiosis. ACS Chem. Neurosci. 11, 3366\u20133376 (2020).","journal-title":"ACS Chem. Neurosci."},{"key":"681_CR121","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1007\/s11064-018-2620-x","volume":"43","author":"F Lai","year":"2018","unstructured":"Lai, F. et al. Intestinal pathology and gut microbiota alterations in a methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson\u2019s disease. Neurochem. Res. 43, 1986\u20131999 (2018).","journal-title":"Neurochem. Res."},{"key":"681_CR122","doi-asserted-by":"publisher","first-page":"1866974","DOI":"10.1080\/19490976.2020.1866974","volume":"13","author":"Y Bhattarai","year":"2021","unstructured":"Bhattarai, Y. et al. Role of gut microbiota in regulating gastrointestinal dysfunction and motor symptoms in a mouse model of Parkinson\u2019s disease. Gut Microbes 13, 1866974 (2021).","journal-title":"Gut Microbes"},{"key":"681_CR123","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3920\/BM2017.0202","volume":"9","author":"P Perez-Pardo","year":"2018","unstructured":"Perez-Pardo, P. et al. Gut bacterial composition in a mouse model of Parkinson\u2019s disease. Benef. Microbes 9, 799\u2013814 (2018).","journal-title":"Benef. Microbes"},{"key":"681_CR124","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3389\/fnagi.2017.00441","volume":"9","author":"X Yang","year":"2017","unstructured":"Yang, X., Qian, Y., Xu, S., Song, Y. & Xiao, Q. Longitudinal analysis of fecal microbiome and pathologic processes in a rotenone induced mice model of Parkinson\u2019s disease. Front. Aging Neurosci. 9, 441 (2017).","journal-title":"Front. Aging Neurosci."},{"key":"681_CR125","doi-asserted-by":"publisher","first-page":"104352","DOI":"10.1016\/j.nbd.2018.12.012","volume":"135","author":"HB Dodiya","year":"2020","unstructured":"Dodiya, H. B. et al. Chronic stress-induced gut dysfunction exacerbates Parkinson\u2019s disease phenotype and pathology in a rotenone-induced mouse model of Parkinson\u2019s disease. Neurobiol. Dis. 135, 104352 (2020).","journal-title":"Neurobiol. Dis."},{"key":"681_CR126","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.neuro.2018.02.013","volume":"65","author":"ME Johnson","year":"2018","unstructured":"Johnson, M. E., Stringer, A. & Bobrovskaya, L. Rotenone induces gastrointestinal pathology and microbiota alterations in a rat model of Parkinson\u2019s disease. Neurotoxicology 65, 174\u2013185 (2018).","journal-title":"Neurotoxicology"},{"key":"681_CR127","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217194","volume":"14","author":"JG Choi","year":"2019","unstructured":"Choi, J. G., Huh, E., Kim, N., Kim, D. H. & Oh, M. S. High-throughput 16S rRNA gene sequencing reveals that 6-hydroxydopamine affects gut microbial environment. PLoS ONE 14, e0217194 (2019).","journal-title":"PLoS ONE"},{"key":"681_CR128","doi-asserted-by":"publisher","first-page":"113159","DOI":"10.1016\/j.expneurol.2019.113159","volume":"325","author":"DN Koutzoumis","year":"2020","unstructured":"Koutzoumis, D. N. et al. Alterations of the gut microbiota with antibiotics protects dopamine neuron loss and improve motor deficits in a pharmacological rodent model of Parkinson\u2019s disease. Exp. Neurol. 325, 113159 (2020).","journal-title":"Exp. Neurol."},{"key":"681_CR129","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/jnc.14299","volume":"145","author":"AM Nixon","year":"2018","unstructured":"Nixon, A. M. et al. HFE genotype restricts the response to paraquat in a mouse model of neurotoxicity. J. Neurochem. 145, 299\u2013311 (2018).","journal-title":"J. Neurochem."},{"key":"681_CR130","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3389\/fnins.2019.01032","volume":"13","author":"Y Singh","year":"2019","unstructured":"Singh, Y. et al. Enriched environmental conditions modify the gut microbiome composition and fecal markers of inflammation in Parkinson\u2019s disease. Front. Neurosci. 13, 1032 (2019).","journal-title":"Front. Neurosci."},{"key":"681_CR131","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.neuro.2019.09.004","volume":"75","author":"S Ghaisas","year":"2019","unstructured":"Ghaisas, S. et al. MitoPark transgenic mouse model recapitulates the gastrointestinal dysfunction and gut-microbiome changes of Parkinson\u2019s disease. Neurotoxicology 75, 186\u2013199 (2019).","journal-title":"Neurotoxicology"},{"key":"681_CR132","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bbi.2018.02.005","volume":"70","author":"MF Sun","year":"2018","unstructured":"Sun, M. F. et al. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson\u2019s disease mice: gut microbiota, glial reaction and TLR4\/TNF-\u03b1 signaling pathway. Brain Behav. Immun. 70, 48\u201360 (2018).","journal-title":"Brain Behav. Immun."},{"key":"681_CR133","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/nn.4030","volume":"18","author":"D Erny","year":"2015","unstructured":"Erny, D. et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat. Neurosci. 18, 965\u2013977 (2015).","journal-title":"Nat. Neurosci."},{"key":"681_CR134","doi-asserted-by":"publisher","first-page":"10609","DOI":"10.3748\/wjg.v21.i37.10609","volume":"21","author":"A Mulak","year":"2015","unstructured":"Mulak, A. & Bonaz, B. Brain-gut-microbiota axis in Parkinson\u2019s disease. World J. Gastroenterol. 21, 10609\u201310620 (2015).","journal-title":"World J. Gastroenterol."},{"key":"681_CR135","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.celrep.2019.12.078","volume":"30","author":"ME Goya","year":"2020","unstructured":"Goya, M. E. et al. Probiotic Bacillus subtilis protects against \u03b1-synuclein aggregation in C. elegans. Cell Rep. 30, 367\u2013380 (2020).","journal-title":"Cell Rep."},{"key":"681_CR136","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/femsre\/fuv036","volume":"40","author":"D Laukens","year":"2016","unstructured":"Laukens, D., Brinkman, B. M., Raes, J., De Vos, M. & Vandenabeele, P. Heterogeneity of the gut microbiome in mice: guidelines for optimizing experimental design. FEMS Microbiol. Rev. 40, 117\u2013132 (2016).","journal-title":"FEMS Microbiol. Rev."},{"key":"681_CR137","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1212\/WNL.57.3.456","volume":"57","author":"RD Abbott","year":"2001","unstructured":"Abbott, R. D. et al. Frequency of bowel movements and the future risk of Parkinson\u2019s disease. Neurology 57, 456\u2013462 (2001).","journal-title":"Neurology"},{"key":"681_CR138","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1016\/j.cgh.2020.08.059","volume":"19","author":"EM Song","year":"2021","unstructured":"Song, E. M. et al. Long-term risks of Parkinson\u2019s disease, surgery, and colorectal cancer in patients with slow-transit constipation. Clin. Gastroenterol. Hepatol. 19, 2577\u20132586 (2021).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"681_CR139","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41531-021-00191-w","volume":"7","author":"M Camacho","year":"2021","unstructured":"Camacho, M. et al. Early constipation predicts faster dementia onset in Parkinson\u2019s disease. NPJ Parkinsons Dis. 7, 45 (2021).","journal-title":"NPJ Parkinsons Dis."},{"key":"681_CR140","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.parkreldis.2020.01.009","volume":"72","author":"JD Jones","year":"2020","unstructured":"Jones, J. D., Rahmani, E., Garcia, E. & Jacobs, J. P. Gastrointestinal symptoms are predictive of trajectories of cognitive functioning in de novo Parkinson\u2019s disease. Parkinsonism Relat. Disord. 72, 7\u201312 (2020).","journal-title":"Parkinsonism Relat. Disord."},{"key":"681_CR141","first-page":"2495","volume":"8","author":"YY Chen","year":"2015","unstructured":"Chen, Y. Y. et al. Clinical characteristics and peripheral T cell subsets in Parkinson\u2019s disease patients with constipation. Int. J. Clin. Exp. Pathol. 8, 2495\u20132504 (2015).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"681_CR142","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.cell.2009.09.033","volume":"139","author":"II Ivanov","year":"2009","unstructured":"Ivanov, I. I. et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139, 485\u2013498 (2009).","journal-title":"Cell"},{"key":"681_CR143","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1097\/MIB.0000000000000714","volume":"22","author":"ML Chen","year":"2016","unstructured":"Chen, M. L. & Sundrud, M. S. Cytokine networks and T-cell subsets in inflammatory bowel diseases. Inflamm. Bowel Dis. 22, 1157\u20131167 (2016).","journal-title":"Inflamm. Bowel Dis."},{"key":"681_CR144","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1001\/jamaneurol.2018.0605","volume":"75","author":"I Peter","year":"2018","unstructured":"Peter, I. et al. Anti-tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease. JAMA Neurol. 75, 939\u2013946 (2018).","journal-title":"JAMA Neurol."},{"key":"681_CR145","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.dld.2018.09.017","volume":"51","author":"F Zhu","year":"2019","unstructured":"Zhu, F. et al. The risk of Parkinson\u2019s disease in inflammatory bowel disease: a systematic review and meta-analysis. Dig. Liver Dis. 51, 38\u201342 (2019).","journal-title":"Dig. Liver Dis."},{"key":"681_CR146","first-page":"408","volume":"70","author":"HS Lee","year":"2021","unstructured":"Lee, H. S., Lobbestael, E., Vermeire, S., Sabino, J. & Cleynen, I. Inflammatory bowel disease and Parkinson\u2019s disease: common pathophysiological links. Gut 70, 408\u2013417 (2021).","journal-title":"Gut"},{"key":"681_CR147","doi-asserted-by":"publisher","first-page":"e1672","DOI":"10.1212\/WNL.0000000000011630","volume":"96","author":"X Kang","year":"2021","unstructured":"Kang, X. et al. Tumor necrosis factor inhibition and Parkinson disease: a Mendelian randomization study. Neurology 96, e1672\u2013e1679 (2021).","journal-title":"Neurology"},{"key":"681_CR148","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1002\/mds.28594","volume":"36","author":"X Kang","year":"2021","unstructured":"Kang, X. et al. Association between microscopic colitis and Parkinson\u2019s disease in a Swedish population. Mov. Disord. 36, 1919\u20131926 (2021).","journal-title":"Mov. Disord."},{"key":"681_CR149","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41531-021-00170-1","volume":"7","author":"MK Herrick","year":"2021","unstructured":"Herrick, M. K. & Tansey, M. G. Is LRRK2 the missing link between inflammatory bowel disease and Parkinson\u2019s disease? NPJ Parkinsons Dis. 7, 26 (2021).","journal-title":"NPJ Parkinsons Dis."},{"key":"681_CR150","doi-asserted-by":"publisher","first-page":"eaai7795","DOI":"10.1126\/scitranslmed.aai7795","volume":"10","author":"KY Hui","year":"2018","unstructured":"Hui, K. Y. et al. Functional variants in the LRRK2 gene confer shared effects on risk for Crohn\u2019s disease and Parkinson\u2019s disease. Sci. Transl. Med. 10, eaai7795 (2018).","journal-title":"Sci. Transl. Med."},{"key":"681_CR151","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1001\/jamaneurol.2017.0469","volume":"74","author":"A Witoelar","year":"2017","unstructured":"Witoelar, A. et al. Genome-wide pleiotropy between Parkinson disease and autoimmune diseases. JAMA Neurol. 74, 780\u2013792 (2017).","journal-title":"JAMA Neurol."},{"key":"681_CR152","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/mds.28890","volume":"37","author":"CH Lin","year":"2022","unstructured":"Lin, C. H. et al. Mild chronic colitis triggers parkinsonism in LRRK2 mutant mice through activating TNF-\u03b1 pathway. Mov. Disord. 37, 745\u2013757 (2022).","journal-title":"Mov. Disord."},{"key":"681_CR153","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41575-020-0286-8","volume":"17","author":"CJ Black","year":"2020","unstructured":"Black, C. J. & Ford, A. C. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat. Rev. Gastroenterol. Hepatol. 17, 473\u2013486 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"681_CR154","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3233\/JPD-202330","volume":"11","author":"TH Mertsalmi","year":"2021","unstructured":"Mertsalmi, T. H., But, A., Pekkonen, E. & Scheperjans, F. Irritable bowel syndrome and risk of Parkinson\u2019s disease in Finland: a nationwide registry-based cohort study. J. Parkinsons Dis. 11, 641\u2013651 (2021).","journal-title":"J. Parkinsons Dis."},{"key":"681_CR155","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10654-014-9878-3","volume":"29","author":"SW Lai","year":"2014","unstructured":"Lai, S. W., Liao, K. F., Lin, C. L. & Sung, F. C. Irritable bowel syndrome correlates with increased risk of Parkinson\u2019s disease in Taiwan. Eur. J. Epidemiol. 29, 57\u201362 (2014).","journal-title":"Eur. J. Epidemiol."},{"key":"681_CR156","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/gutjnl-2018-316937","volume":"68","author":"P Weimers","year":"2019","unstructured":"Weimers, P. et al. Association between inflammatory bowel disease and Parkinson\u2019s disease: seek and you shall find? Gut 68, 175\u2013176 (2019).","journal-title":"Gut"},{"key":"681_CR157","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1007\/s00415-021-10688-2","volume":"269","author":"SY Yoon","year":"2022","unstructured":"Yoon, S. Y. et al. Irritable bowel syndrome and subsequent risk of Parkinson\u2019s disease: a nationwide population-based matched-cohort study. J. Neurol. 269, 1404\u20131412 (2022).","journal-title":"J. Neurol."},{"key":"681_CR158","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41531-020-00145-8","volume":"7","author":"B Liu","year":"2021","unstructured":"Liu, B. et al. Irritable bowel syndrome and Parkinson\u2019s disease risk: register-based studies. NPJ Parkinsons Dis. 7, 5 (2021).","journal-title":"NPJ Parkinsons Dis."},{"key":"681_CR159","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/ana.24518","volume":"78","author":"E Svensson","year":"2015","unstructured":"Svensson, E. et al. Does vagotomy reduce the risk of Parkinson\u2019s disease: the authors reply. Ann. Neurol. 78, 1012\u20131013 (2015).","journal-title":"Ann. Neurol."},{"key":"681_CR160","doi-asserted-by":"publisher","first-page":"eaar5280","DOI":"10.1126\/scitranslmed.aar5280","volume":"10","author":"BA Killinger","year":"2018","unstructured":"Killinger, B. A. et al. The vermiform appendix impacts the risk of developing Parkinson\u2019s disease. Sci. Transl. Med. 10, eaar5280 (2018).","journal-title":"Sci. Transl. Med."},{"key":"681_CR161","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1002\/mds.28553","volume":"36","author":"Y Chen","year":"2021","unstructured":"Chen, Y. et al. Increased accumulation of \u03b1-synuclein in inflamed appendices of Parkinson\u2019s disease patients. Mov. Disord. 36, 1911\u20131918 (2021).","journal-title":"Mov. Disord."},{"key":"681_CR162","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3389\/fneur.2020.00510","volume":"11","author":"B Liu","year":"2020","unstructured":"Liu, B., Fang, F., Ye, W. & Wirdefeldt, K. Appendectomy, tonsillectomy and Parkinson\u2019s disease risk: a Swedish register-based study. Front. Neurol. 11, 510 (2020).","journal-title":"Front. Neurol."},{"key":"681_CR163","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/mds.26670","volume":"31","author":"C Marras","year":"2016","unstructured":"Marras, C., Lang, A. E., Austin, P. C., Lau, C. & Urbach, D. R. Appendectomy in mid and later life and risk of Parkinson\u2019s disease: a population-based study. Mov. Disord. 31, 1243\u20131247 (2016).","journal-title":"Mov. Disord."},{"key":"681_CR164","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1002\/mds.26761","volume":"31","author":"E Svensson","year":"2016","unstructured":"Svensson, E. et al. Appendectomy and risk of Parkinson\u2019s disease: a nationwide cohort study with more than 10 years of follow-up. Mov. Disord. 31, 1918\u20131922 (2016).","journal-title":"Mov. Disord."},{"key":"681_CR165","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1002\/mds.109","volume":"33","author":"N Palacios","year":"2018","unstructured":"Palacios, N., Hughes, K. C., Cereda, E., Schwarzschild, M. A. & Ascherio, A. Appendectomy and risk of Parkinson\u2019s disease in two large prospective cohorts of men and women. Mov. Disord. 33, 1492\u20131496 (2018).","journal-title":"Mov. Disord."},{"key":"681_CR166","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/metabo11010029","volume":"11","author":"P Li","year":"2021","unstructured":"Li, P. et al. Gut microbiota dysbiosis is associated with elevated bile acids in Parkinson\u2019s disease. Metabolites 11, 29 (2021).","journal-title":"Metabolites"},{"key":"681_CR167","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1053\/j.gastro.2019.02.036","volume":"156","author":"X Yao","year":"2019","unstructured":"Yao, X. & Smolka, A. J. Gastric parietal cell physiology and Helicobacter pylori-induced disease. Gastroenterology 156, 2158\u20132173 (2019).","journal-title":"Gastroenterology"},{"key":"681_CR168","doi-asserted-by":"publisher","first-page":"165","DOI":"10.14309\/ajg.0000000000000501","volume":"115","author":"M Pimentel","year":"2020","unstructured":"Pimentel, M., Saad, R. J., Long, M. D. & Rao, S. S. C. ACG Clinical Guideline: small intestinal bacterial overgrowth. Am. J. Gastroenterol. 115, 165\u2013178 (2020).","journal-title":"Am. J. Gastroenterol."},{"key":"681_CR169","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/j.1468-1331.2011.03643.x","volume":"19","author":"HH Nielsen","year":"2012","unstructured":"Nielsen, H. H., Qiu, J., Friis, S., Wermuth, L. & Ritz, B. Treatment for Helicobacter pylori infection and risk of Parkinson\u2019s disease in Denmark. Eur. J. Neurol. 19, 864\u2013869 (2012).","journal-title":"Eur. J. Neurol."},{"key":"681_CR170","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.parkreldis.2017.11.331","volume":"47","author":"HK Huang","year":"2018","unstructured":"Huang, H. K. et al. Helicobacter pylori infection is associated with an increased risk of Parkinson\u2019s disease: a population-based retrospective cohort study. Parkinsonism Relat. Disord. 47, 26\u201331 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"681_CR171","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.parkreldis.2014.12.009","volume":"21","author":"AH Tan","year":"2015","unstructured":"Tan, A. H. et al. Helicobacter pylori infection is associated with worse severity of Parkinson\u2019s disease. Parkinsonism Relat. Disord. 21, 221\u2013225 (2015).","journal-title":"Parkinsonism Relat. Disord."},{"key":"681_CR172","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1007\/s00415-013-7089-6","volume":"260","author":"KE Rahne","year":"2013","unstructured":"Rahne, K. E., Tagesson, C. & Nyholm, D. Motor fluctuations and Helicobacter pylori in Parkinson\u2019s disease. J. Neurol. 260, 2974\u20132980 (2013).","journal-title":"J. Neurol."},{"key":"681_CR173","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.gtc.2017.09.008","volume":"47","author":"A Adike","year":"2018","unstructured":"Adike, A. & DiBaise, J. K. Small intestinal bacterial overgrowth: nutritional implications, diagnosis, and management. Gastroenterol. Clin. North. Am. 47, 193\u2013208 (2018).","journal-title":"Gastroenterol. Clin. North. Am."},{"key":"681_CR174","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.parkreldis.2014.02.019","volume":"20","author":"AH Tan","year":"2014","unstructured":"Tan, A. H. et al. Small intestinal bacterial overgrowth in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 20, 535\u2013540 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"681_CR175","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s00702-016-1612-8","volume":"123","author":"XL Niu","year":"2016","unstructured":"Niu, X. L. et al. Prevalence of small intestinal bacterial overgrowth in Chinese patients with Parkinson\u2019s disease. J. Neural Transm. 123, 1381\u20131386 (2016).","journal-title":"J. Neural Transm."},{"key":"681_CR176","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1002\/mds.22190","volume":"23","author":"WY Lee","year":"2008","unstructured":"Lee, W. Y., Yoon, W. T., Shin, H. Y., Jeon, S. H. & Rhee, P. L. Helicobacter pylori infection and motor fluctuations in patients with Parkinson\u2019s disease. Mov. Disord. 23, 1696\u20131700 (2008).","journal-title":"Mov. Disord."},{"key":"681_CR177","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/mds.25522","volume":"28","author":"A Fasano","year":"2013","unstructured":"Fasano, A. et al. The role of small intestinal bacterial overgrowth in Parkinson\u2019s disease. Mov. Disord. 28, 1241\u20131249 (2013).","journal-title":"Mov. Disord."},{"key":"681_CR178","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1212\/01.wnl.0000221672.01272.ba","volume":"66","author":"M Pierantozzi","year":"2006","unstructured":"Pierantozzi, M. et al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 66, 1824\u20131829 (2006).","journal-title":"Neurology"},{"key":"681_CR179","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3233\/JPD-181327","volume":"8","author":"DJ McGee","year":"2018","unstructured":"McGee, D. J., Lu, X. H. & Disbrow, E. A. Stomaching the possibility of a pathogenic role for Helicobacter pylori in Parkinson\u2019s disease. J. Parkinsons Dis. 8, 367\u2013374 (2018).","journal-title":"J. Parkinsons Dis."},{"key":"681_CR180","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153725","volume":"11","author":"G Suwarnalata","year":"2016","unstructured":"Suwarnalata, G. et al. Augmentation of autoantibodies by Helicobacter pylori in Parkinson\u2019s disease patients may be linked to greater severity. PLoS ONE 11, e0153725 (2016).","journal-title":"PLoS ONE"},{"key":"681_CR181","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1001\/jamaneurol.2017.1125","volume":"74","author":"E De Pablo-Fernandez","year":"2017","unstructured":"De Pablo-Fernandez, E. et al. Association of autonomic dysfunction with disease progression and survival in Parkinson disease. JAMA Neurol. 74, 970\u2013976 (2017).","journal-title":"JAMA Neurol."},{"key":"681_CR182","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/mds.27105","volume":"33","author":"A Heintz-Buschart","year":"2018","unstructured":"Heintz-Buschart, A. et al. The nasal and gut microbiome in Parkinson\u2019s disease and idiopathic rapid eye movement sleep behavior disorder. Mov. Disord. 33, 88\u201398 (2018).","journal-title":"Mov. Disord."},{"key":"681_CR183","doi-asserted-by":"publisher","first-page":"e00797-20","DOI":"10.1128\/mSystems.00797-20","volume":"5","author":"H Nishiwaki","year":"2020","unstructured":"Nishiwaki, H. et al. Short-chain fatty acid-producing gut microbiota is decreased in Parkinson\u2019s disease but not in rapid-eye-movement sleep behavior disorder. mSystems 5, e00797-20 (2020).","journal-title":"mSystems"},{"key":"681_CR184","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/ana.25788","volume":"88","author":"S Heinzel","year":"2020","unstructured":"Heinzel, S. et al. Gut microbiome signatures of risk and prodromal markers of Parkinson disease. Ann. Neurol. 88, 320\u2013331 (2020).","journal-title":"Ann. Neurol."},{"key":"681_CR185","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1007\/s00415-019-09320-1","volume":"267","author":"M Lubomski","year":"2020","unstructured":"Lubomski, M. et al. Parkinson\u2019s disease and the gastrointestinal microbiome. J. Neurol. 267, 2507\u20132523 (2020).","journal-title":"J. Neurol."},{"key":"681_CR186","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/biom11020144","volume":"11","author":"S Vascellari","year":"2021","unstructured":"Vascellari, S. et al. Clinical phenotypes of Parkinson\u2019s disease associate with distinct gut microbiota and metabolome enterotypes. Biomolecules 11, 144 (2021).","journal-title":"Biomolecules"},{"key":"681_CR187","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/mds.26069","volume":"30","author":"F Scheperjans","year":"2015","unstructured":"Scheperjans, F. et al. Gut microbiota are related to Parkinson\u2019s disease and clinical phenotype. Mov. Disord. 30, 350\u2013358 (2015).","journal-title":"Mov. Disord."},{"key":"681_CR188","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3233\/JPD-202297","volume":"11","author":"R Cilia","year":"2021","unstructured":"Cilia, R. et al. Does gut microbiota influence the course of Parkinson\u2019s disease? A 3-year prospective exploratory study in de novo patients. J. Parkinsons Dis. 11, 159\u2013170 (2021).","journal-title":"J. Parkinsons Dis."},{"key":"681_CR189","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187307","volume":"12","author":"T Minato","year":"2017","unstructured":"Minato, T. et al. Progression of Parkinson\u2019s disease is associated with gut dysbiosis: two-year follow-up study. PLoS ONE 12, e0187307 (2017).","journal-title":"PLoS ONE"},{"key":"681_CR190","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ebiom.2019.05.064","volume":"44","author":"VTE Aho","year":"2019","unstructured":"Aho, V. T. E. et al. Gut microbiota in Parkinson\u2019s disease: temporal stability and relations to disease progression. EBioMedicine 44, 691\u2013707 (2019).","journal-title":"EBioMedicine"},{"key":"681_CR191","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/mds.28016","volume":"35","author":"C Shin","year":"2020","unstructured":"Shin, C., Lim, Y., Lim, H. & Ahn, T. B. Plasma short-chain fatty acids in patients with Parkinson\u2019s disease. Mov. Disord. 35, 1021\u20131027 (2020).","journal-title":"Mov. Disord."},{"key":"681_CR192","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.3233\/JPD-212604","volume":"11","author":"X He","year":"2021","unstructured":"He, X. et al. Plasma short-chain fatty acids differences in multiple system atrophy from Parkinson\u2019s disease. J. Parkinsons Dis. 11, 1167\u20131176 (2021).","journal-title":"J. Parkinsons Dis."},{"key":"681_CR193","doi-asserted-by":"publisher","first-page":"e848","DOI":"10.1212\/WNL.0000000000013225","volume":"98","author":"SJ Chen","year":"2022","unstructured":"Chen, S. J. et al. Association of fecal and plasma levels of short-chain fatty acids with gut microbiota and clinical severity in Parkinson disease patients. Neurology 98, e848\u2013e858 (2022).","journal-title":"Neurology"},{"key":"681_CR194","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3390\/nu10101398","volume":"10","author":"MH Janeiro","year":"2018","unstructured":"Janeiro, M. H., Ramirez, M. J., Milagro, F. I., Martinez, J. A. & Solas, M. Implication of trimethylamine N-oxide (TMAO) in disease: potential biomarker or new therapeutic target. Nutrients 10, 1398 (2018).","journal-title":"Nutrients"},{"key":"681_CR195","doi-asserted-by":"publisher","first-page":"111090","DOI":"10.1016\/j.nut.2020.111090","volume":"83","author":"SJ Chung","year":"2021","unstructured":"Chung, S. J. et al. Gut microbiota-derived metabolite trimethylamine N-oxide as a biomarker in early Parkinson\u2019s disease. Nutrition 83, 111090 (2021).","journal-title":"Nutrition"},{"key":"681_CR196","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.cca.2019.10.038","volume":"501","author":"B Sankowski","year":"2020","unstructured":"Sankowski, B. et al. Higher cerebrospinal fluid to plasma ratio of p-cresol sulfate and indoxyl sulfate in patients with Parkinson\u2019s disease. Clin. Chim. Acta 501, 165\u2013173 (2020).","journal-title":"Clin. Chim. Acta"},{"key":"681_CR197","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1002\/mds.28246","volume":"35","author":"SJ Chen","year":"2020","unstructured":"Chen, S. J. et al. The gut metabolite trimethylamine N-oxide is associated with Parkinson\u2019s disease severity and progression. Mov. Disord. 35, 2115\u20132116 (2020).","journal-title":"Mov. Disord."},{"key":"681_CR198","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1126\/science.aau5812","volume":"362","author":"CL Gentile","year":"2018","unstructured":"Gentile, C. L. & Weir, T. L. The gut microbiota at the intersection of diet and human health. Science 362, 776\u2013780 (2018).","journal-title":"Science"},{"key":"681_CR199","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41575-018-0061-2","volume":"16","author":"N Zmora","year":"2019","unstructured":"Zmora, N., Suez, J. & Elinav, E. You are what you eat: diet, health and the gut microbiota. Nat. Rev. Gastroenterol. Hepatol. 16, 35\u201356 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"681_CR200","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.3390\/nu11081896","volume":"11","author":"C Boulos","year":"2019","unstructured":"Boulos, C., Yaghi, N., El Hayeck, R., Heraoui, G. N. & Fakhoury-Sayegh, N. Nutritional risk factors, microbiota and Parkinson\u2019s disease: what is the current evidence? Nutrients 11, 1896 (2019).","journal-title":"Nutrients"},{"key":"681_CR201","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/ggi.12321","volume":"15","author":"A Wang","year":"2015","unstructured":"Wang, A., Lin, Y., Wu, Y. & Zhang, D. Macronutrients intake and risk of Parkinson\u2019s disease: a meta-analysis. Geriatr. Gerontol. Int. 15, 606\u2013616 (2015).","journal-title":"Geriatr. Gerontol. Int."},{"key":"681_CR202","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/iub.1428","volume":"67","author":"R Marion-Letellier","year":"2015","unstructured":"Marion-Letellier, R., Savoye, G. & Ghosh, S. Polyunsaturated fatty acids and inflammation. IUBMB Life 67, 659\u2013667 (2015).","journal-title":"IUBMB Life"},{"key":"681_CR203","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1002\/mds.28173","volume":"35","author":"AF Ying","year":"2020","unstructured":"Ying, A. F. et al. Dietary antioxidants and risk of Parkinson\u2019s disease in the Singapore Chinese Health Study. Mov. Disord. 35, 1765\u20131773 (2020).","journal-title":"Mov. Disord."},{"key":"681_CR204","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1212\/WNL.0000000000011373","volume":"96","author":"E Hantikainen","year":"2021","unstructured":"Hantikainen, E. et al. Dietary antioxidants and the risk of Parkinson disease: the Swedish National March Cohort. Neurology 96, e895\u2013e903 (2021).","journal-title":"Neurology"},{"key":"681_CR205","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1002\/mds.27120","volume":"32","author":"F Yang","year":"2017","unstructured":"Yang, F., Wolk, A., Hakansson, N., Pedersen, N. L. & Wirdefeldt, K. Dietary antioxidants and risk of Parkinson\u2019s disease in two population-based cohorts. Mov. Disord. 32, 1631\u20131636 (2017).","journal-title":"Mov. Disord."},{"key":"681_CR206","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1002\/mds.26819","volume":"31","author":"KC Hughes","year":"2016","unstructured":"Hughes, K. C. et al. Intake of antioxidant vitamins and risk of Parkinson\u2019s disease. Mov. Disord. 31, 1909\u20131914 (2016).","journal-title":"Mov. Disord."},{"key":"681_CR207","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1016\/j.clnu.2021.05.011","volume":"40","author":"MC Chang","year":"2021","unstructured":"Chang, M. C., Kwak, S. G. & Kwak, S. Effect of dietary vitamins C and E on the risk of Parkinson\u2019s disease: a meta-analysis. Clin. Nutr. 40, 3922\u20133930 (2021).","journal-title":"Clin. Nutr."},{"key":"681_CR208","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000355849","volume":"42","author":"A Takeda","year":"2014","unstructured":"Takeda, A. et al. Vitamin A and carotenoids and the risk of Parkinson\u2019s disease: a systematic review and meta-analysis. Neuroepidemiology 42, 25\u201338 (2014).","journal-title":"Neuroepidemiology"},{"key":"681_CR209","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1212\/01.wnl.0000225050.57553.6d","volume":"67","author":"LML de Lau","year":"2006","unstructured":"de Lau, L. M. L., Koudstaal, P. J., Witteman, J. C., Hofman, A. & Breteler, M. M. Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology 67, 315\u2013318 (2006).","journal-title":"Neurology"},{"key":"681_CR210","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1017\/S0007114510001005","volume":"104","author":"K Murakami","year":"2010","unstructured":"Murakami, K. et al. Dietary intake of folate, vitamin B6, vitamin B12 and riboflavin and risk of Parkinson\u2019s disease: a case-control study in Japan. Br. J. Nutr. 104, 757\u2013764 (2010).","journal-title":"Br. J. Nutr."},{"key":"681_CR211","doi-asserted-by":"publisher","first-page":"7197","DOI":"10.3390\/nu7095333","volume":"7","author":"L Shen","year":"2015","unstructured":"Shen, L. Associations between B vitamins and Parkinson\u2019s disease. Nutrients 7, 7197\u20137208 (2015).","journal-title":"Nutrients"},{"key":"681_CR212","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/aje\/kwh213","volume":"160","author":"H Chen","year":"2004","unstructured":"Chen, H. et al. Folate intake and risk of Parkinson\u2019s disease. Am. J. Epidemiol. 160, 368\u2013375 (2004).","journal-title":"Am. J. Epidemiol."},{"key":"681_CR213","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1002\/acn3.51227","volume":"7","author":"X Fan","year":"2020","unstructured":"Fan, X. et al. Role of homocysteine in the development and progression of Parkinson\u2019s disease. Ann. Clin. Transl. Neurol. 7, 2332\u20132338 (2020).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"681_CR214","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.neurobiolaging.2021.06.023","volume":"108","author":"Y Zhao","year":"2021","unstructured":"Zhao, Y. et al. Investigating the causality of metabolites involved in one-carbon metabolism with the risk and age at onset of Parkinson\u2019s disease: a two-sample Mendelian randomization study. Neurobiol. Aging 108, 196\u2013199 (2021).","journal-title":"Neurobiol. Aging"},{"key":"681_CR215","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/mds.27301","volume":"33","author":"CW Christine","year":"2018","unstructured":"Christine, C. W. et al. Vitamin B12 and homocysteine levels predict different outcomes in early Parkinson\u2019s disease. Mov. Disord. 33, 762\u2013770 (2018).","journal-title":"Mov. Disord."},{"key":"681_CR216","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3233\/JPD-181535","volume":"9","author":"I Sleeman","year":"2019","unstructured":"Sleeman, I. et al. Urate and homocysteine: predicting motor and cognitive changes in newly diagnosed Parkinson\u2019s disease. J. Parkinsons Dis. 9, 351\u2013359 (2019).","journal-title":"J. Parkinsons Dis."},{"key":"681_CR217","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1007\/s10072-015-2349-0","volume":"36","author":"P Cheng","year":"2015","unstructured":"Cheng, P. et al. Dietary intake of iron, zinc, copper, and risk of Parkinson\u2019s disease: a meta-analysis. Neurol. Sci. 36, 2269\u20132275 (2015).","journal-title":"Neurol. Sci."},{"key":"681_CR218","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1002\/mds.25076","volume":"27","author":"N Palacios","year":"2012","unstructured":"Palacios, N. et al. Caffeine and risk of Parkinson\u2019s disease in a large cohort of men and women. Mov. Disord. 27, 1276\u20131282 (2012).","journal-title":"Mov. Disord."},{"key":"681_CR219","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/ggi.12123","volume":"14","author":"H Qi","year":"2014","unstructured":"Qi, H. & Li, S. Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson\u2019s disease. Geriatr. Gerontol. Int. 14, 430\u2013439 (2014).","journal-title":"Geriatr. Gerontol. Int."},{"key":"681_CR220","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.parkreldis.2020.10.024","volume":"80","author":"JF Chen","year":"2020","unstructured":"Chen, J. F. & Schwarzschild, M. A. Do caffeine and more selective adenosine A2A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson\u2019s disease? Parkinonism Relat. Disord. 80, S45\u2013S53 (2020).","journal-title":"Parkinonism Relat. Disord."},{"key":"681_CR221","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/nu13010088","volume":"13","author":"A Iriondo-DeHond","year":"2020","unstructured":"Iriondo-DeHond, A., Uranga, J. A., Del Castillo, M. D. & Abalo, R. Effects of coffee and its components on the gastrointestinal tract and the brain-gut axis. Nutrients 13, 88 (2020).","journal-title":"Nutrients"},{"key":"681_CR222","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/ana.24385","volume":"77","author":"RB Postuma","year":"2015","unstructured":"Postuma, R. B. et al. Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study. Ann. Neurol. 77, 830\u2013839 (2015).","journal-title":"Ann. Neurol."},{"key":"681_CR223","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1212\/WNL.0b013e31824f7fc4","volume":"78","author":"X Gao","year":"2012","unstructured":"Gao, X., Cassidy, A., Schwarzschild, M. A., Rimm, E. B. & Ascherio, A. Habitual intake of dietary flavonoids and risk of Parkinson disease. Neurology 78, 1138\u20131145 (2012).","journal-title":"Neurology"},{"key":"681_CR224","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1212\/WNL.0000000000002351","volume":"86","author":"X Gao","year":"2016","unstructured":"Gao, X., O\u2019 Reilly, \u00c9. J., Schwarzschild, M. A. & Ascherio, A. Prospective study of plasma urate and risk of Parkinson disease in men and women. Neurology 86, 520\u2013526 (2016).","journal-title":"Neurology"},{"key":"681_CR225","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/aje\/kwm385","volume":"167","author":"X Gao","year":"2008","unstructured":"Gao, X. et al. Diet, urate, and Parkinson\u2019s disease risk in men. Am. J. Epidemiol. 167, 831\u2013838 (2008).","journal-title":"Am. J. Epidemiol."},{"key":"681_CR226","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1212\/WNL.0000000000008191","volume":"93","author":"A Chamorro","year":"2019","unstructured":"Chamorro, A. & Mir, P. Raising serum urate levels in Parkinson disease: a strategy only for women? Neurology 93, 611\u2013612 (2019).","journal-title":"Neurology"},{"key":"681_CR227","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1212\/WNL.0000000000004057","volume":"89","author":"KC Hughes","year":"2017","unstructured":"Hughes, K. C. et al. Intake of dairy foods and risk of Parkinson disease. Neurology 89, 46\u201352 (2017).","journal-title":"Neurology"},{"key":"681_CR228","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s10654-014-9921-4","volume":"29","author":"W Jiang","year":"2014","unstructured":"Jiang, W., Ju, C., Jiang, H. & Zhang, D. Dairy foods intake and risk of Parkinson\u2019s disease: a dose-response meta-analysis of prospective cohort studies. Eur. J. Epidemiol. 29, 613\u2013619 (2014).","journal-title":"Eur. J. Epidemiol."},{"key":"681_CR229","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s00415-018-9032-3","volume":"266","author":"FJ Jimenez-Jimenez","year":"2019","unstructured":"Jimenez-Jimenez, F. J., Alonso-Navarro, H., Garcia-Martin, E. & Agundez, J. A. G. Alcohol consumption and risk for Parkinson\u2019s disease: a systematic review and meta-analysis. J. Neurol. 266, 1821\u20131834 (2019).","journal-title":"J. Neurol."},{"key":"681_CR230","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/mds.28039","volume":"35","author":"S Peters","year":"2020","unstructured":"Peters, S. et al. Alcohol consumption and risk of Parkinson\u2019s disease: data from a large prospective European cohort. Mov. Disord. 35, 1258\u20131263 (2020).","journal-title":"Mov. Disord."},{"key":"681_CR231","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/mds.27933","volume":"35","author":"IY Kim","year":"2020","unstructured":"Kim, I. Y. et al. Alcohol intake and Parkinson\u2019s disease risk in the Million Women Study. Mov. Disord. 35, 443\u2013449 (2020).","journal-title":"Mov. Disord."},{"key":"681_CR232","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.parkreldis.2019.12.006","volume":"71","author":"R Kim","year":"2020","unstructured":"Kim, R., Yoo, D., Jung, Y. J., Han, K. & Lee, J. Y. Sex differences in smoking, alcohol consumption, and risk of Parkinson\u2019s disease: a nationwide cohort study. Parkinsonism Relat. Disord. 71, 60\u201365 (2020).","journal-title":"Parkinsonism Relat. Disord."},{"key":"681_CR233","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1136\/jnnp-2020-323646","volume":"91","author":"BM Jacobs","year":"2020","unstructured":"Jacobs, B. M. et al. Parkinson\u2019s disease determinants, prediction and gene\u2013environment interactions in the UK Biobank. J. Neurol. Neurosurg. Psychiatry 91, 1046\u20131054 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"681_CR234","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/mds.27577","volume":"34","author":"KC Paul","year":"2019","unstructured":"Paul, K. C. et al. The association between lifestyle factors and Parkinson\u2019s disease progression and mortality. Mov. Disord. 34, 58\u201366 (2019).","journal-title":"Mov. Disord."},{"key":"681_CR235","doi-asserted-by":"crossref","unstructured":"Kim, J. J., Bandres-Ciga, S., Blauwendraat, C. & Gan-Or, Z. International Parkinson\u2019s Disease Genomics ConsortiumNo genetic evidence for involvement of alcohol dehydrogenase genes in risk for Parkinson\u2019s disease. Neurobiol. Aging 87, 140.e19\u2013140.e22 (2020).","DOI":"10.1016\/j.neurobiolaging.2019.11.006"},{"key":"681_CR236","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1093\/ajcn\/86.5.1486","volume":"86","author":"X Gao","year":"2007","unstructured":"Gao, X. et al. Prospective study of dietary pattern and risk of Parkinson disease. Am. J. Clin. Nutr. 86, 1486\u20131494 (2007).","journal-title":"Am. J. Clin. Nutr."},{"key":"681_CR237","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/mds.28314","volume":"36","author":"W Yin","year":"2021","unstructured":"Yin, W., Lof, M., Pedersen, N. L., Sandin, S. & Fang, F. Mediterranean dietary pattern at middle age and risk of Parkinson\u2019s disease: a Swedish cohort study. Mov. Disord. 36, 255\u2013260 (2021).","journal-title":"Mov. Disord."},{"key":"681_CR238","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/mds.27489","volume":"34","author":"MI Maraki","year":"2019","unstructured":"Maraki, M. I. et al. Mediterranean diet adherence is related to reduced probability of prodromal Parkinson\u2019s disease. Mov. Disord. 34, 48\u201357 (2019).","journal-title":"Mov. Disord."},{"key":"681_CR239","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/mds.24918","volume":"27","author":"RN Alcalay","year":"2012","unstructured":"Alcalay, R. N. et al. The association between Mediterranean diet adherence and Parkinson\u2019s disease. Mov. Disord. 27, 771\u2013774 (2012).","journal-title":"Mov. Disord."},{"key":"681_CR240","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/mds.28464","volume":"36","author":"A Metcalfe-Roach","year":"2021","unstructured":"Metcalfe-Roach, A. et al. MIND and Mediterranean diets associated with later onset of Parkinson\u2019s disease. Mov. Disord. 36, 977\u2013984 (2021).","journal-title":"Mov. Disord."},{"key":"681_CR241","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.parkreldis.2017.06.007","volume":"42","author":"E Cassani","year":"2017","unstructured":"Cassani, E. et al. Dietary habits in Parkinson\u2019s disease: adherence to Mediterranean diet. Parkinsonism Relat. Disord. 42, 40\u201346 (2017).","journal-title":"Parkinsonism Relat. Disord."},{"key":"681_CR242","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/gerona\/glx227","volume":"73","author":"V Tosti","year":"2018","unstructured":"Tosti, V., Bertozzi, B. & Fontana, L. Health benefits of the Mediterranean diet: metabolic and molecular mechanisms. J. Gerontol. A Biol. Sci. Med. Sci. 73, 318\u2013326 (2018).","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"681_CR243","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/s41579-019-0256-8","volume":"17","author":"AA Kolodziejczyk","year":"2019","unstructured":"Kolodziejczyk, A. A., Zheng, D. & Elinav, E. Diet\u2013microbiota interactions and personalized nutrition. Nat. Rev. Microbiol. 17, 742\u2013753 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"681_CR244","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/mds.28411","volume":"36","author":"EM Kline","year":"2021","unstructured":"Kline, E. M. et al. Genetic and environmental factors in Parkinson\u2019s disease converge on immune function and inflammation. Mov. Disord. 36, 25\u201336 (2021).","journal-title":"Mov. Disord."},{"key":"681_CR245","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.4049\/jimmunol.1000548","volume":"185","author":"A Gardet","year":"2010","unstructured":"Gardet, A. et al. LRRK2 is involved in the IFN-\u03b3 response and host response to pathogens. J. Immunol. 185, 5577\u20135585 (2010).","journal-title":"J. Immunol."},{"key":"681_CR246","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41531-017-0010-8","volume":"3","author":"DA Cook","year":"2017","unstructured":"Cook, D. A. et al. LRRK2 levels in immune cells are increased in Parkinson\u2019s disease. NPJ Parkinsons Dis. 3, 11 (2017).","journal-title":"NPJ Parkinsons Dis."},{"key":"681_CR247","doi-asserted-by":"publisher","first-page":"eaan8162","DOI":"10.1126\/scitranslmed.aan8162","volume":"10","author":"T Takagawa","year":"2018","unstructured":"Takagawa, T. et al. An increase in LRRK2 suppresses autophagy and enhances Dectin-1-induced immunity in a mouse model of colitis. Sci. Transl. Med. 10, eaan8162 (2018).","journal-title":"Sci. Transl. Med."},{"key":"681_CR248","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/mds.28347","volume":"36","author":"E Menozzi","year":"2021","unstructured":"Menozzi, E., Macnaughtan, J. & Schapira, A. H. V. LRRK2 parkinsonism: does the response to gut bacteria mitigate the neurological picture? Mov. Disord. 36, 71\u201375 (2021).","journal-title":"Mov. Disord."},{"key":"681_CR249","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41531-021-00218-2","volume":"7","author":"ZD Wallen","year":"2021","unstructured":"Wallen, Z. D. et al. Exploring human-genome gut\u2013microbiome interaction in Parkinson\u2019s disease. NPJ Parkinsons Dis. 7, 74 (2021).","journal-title":"NPJ Parkinsons Dis."},{"key":"681_CR250","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.parkreldis.2020.08.015","volume":"79","author":"AH Tan","year":"2020","unstructured":"Tan, A. H. et al. PINK1 p.Leu347Pro mutations in Malays: prevalence and illustrative cases. Parkinsonism Relat. Disord. 79, 34\u201339 (2020).","journal-title":"Parkinsonism Relat. Disord."},{"key":"681_CR251","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.parkreldis.2018.06.003","volume":"55","author":"K Knudsen","year":"2018","unstructured":"Knudsen, K., Szwebs, M., Hansen, A. K. & Borghammer, P. Gastric emptying in Parkinson\u2019s disease \u2013 a mini-review. Parkinsonism Relat. Disord. 55, 18\u201325 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"681_CR252","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.parkreldis.2020.05.001","volume":"76","author":"RF Pfeiffer","year":"2020","unstructured":"Pfeiffer, R. F., Isaacson, S. H. & Pahwa, R. Clinical implications of gastric complications on levodopa treatment in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 76, 63\u201371 (2020).","journal-title":"Parkinsonism Relat. Disord."},{"key":"681_CR253","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1517\/14656566.2015.1086747","volume":"16","author":"JL Barboza","year":"2015","unstructured":"Barboza, J. L., Okun, M. S. & Moshiree, B. The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson\u2019s disease. Expert. Opin. Pharmacother. 16, 2449\u20132464 (2015).","journal-title":"Expert. Opin. Pharmacother."},{"key":"681_CR254","unstructured":"Lim, S. Y. & Tan, A. H. in Parkinson\u2019s Disease: Current and Future Therapeutics and Clinical Trials (eds Galvez-Jimenez, N. et al.) 93\u2013109 (Cambridge Univ. Press, 2016)."},{"key":"681_CR255","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/mds.28219","volume":"35","author":"JH Choi","year":"2020","unstructured":"Choi, J. H. et al. Double-blind, randomized, placebo-controlled trial of DA-9701 in Parkinson\u2019s disease: PASS-GI Study. Mov. Disord. 35, 1966\u20131976 (2020).","journal-title":"Mov. Disord."},{"key":"681_CR256","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/mds.27259","volume":"33","author":"SL Marrinan","year":"2018","unstructured":"Marrinan, S. L. et al. A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson\u2019s disease. Mov. Disord. 33, 329\u2013332 (2018).","journal-title":"Mov. Disord."},{"key":"681_CR257","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.clinthera.2020.04.004","volume":"42","author":"BE Safirstein","year":"2020","unstructured":"Safirstein, B. E. et al. Pharmacokinetics of inhaled levodopa administered with oral carbidopa in the fed state in patients with Parkinson\u2019s disease. Clin. Ther. 42, 1034\u20131046 (2020).","journal-title":"Clin. Ther."},{"key":"681_CR258","doi-asserted-by":"publisher","first-page":"360ra136","DOI":"10.1126\/scitranslmed.aad8858","volume":"8","author":"MM Lipp","year":"2016","unstructured":"Lipp, M. M., Batycky, R., Moore, J., Leinonen, M. & Freed, M. I. Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson\u2019s disease. Sci. Transl. Med. 8, 360ra136 (2016).","journal-title":"Sci. Transl. Med."},{"key":"681_CR259","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/00002826-198712000-00004","volume":"10","author":"AC Baruzzi","year":"1987","unstructured":"Baruzzi, A. C. et al. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in Parkinsonian patients. Clin. Neuropharmacol. 10, 527\u2013537 (1987).","journal-title":"Clin. Neuropharmacol."},{"key":"681_CR260","doi-asserted-by":"publisher","first-page":"e1487","DOI":"10.1212\/WNL.0000000000007173","volume":"92","author":"C Trenkwalder","year":"2019","unstructured":"Trenkwalder, C., Kuoppamaki, M., Vahteristo, M., Muller, T. & Ellmen, J. Increased dose of carbidopa with levodopa and entacapone improves \u201coff\u201d time in a randomized trial. Neurology 92, e1487\u2013e1496 (2019).","journal-title":"Neurology"},{"key":"681_CR261","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1002\/mds.28248","volume":"35","author":"AH Tan","year":"2020","unstructured":"Tan, A. H. et al. Helicobacter pylori eradication in Parkinson\u2019s disease: a randomized placebo-controlled trial. Mov. Disord. 35, 2250\u20132260 (2020).","journal-title":"Mov. Disord."},{"key":"681_CR262","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/00002826-199210000-00004","volume":"15","author":"R Astarloa","year":"1992","unstructured":"Astarloa, R., Mena, M. A., S\u00e1nchez, V., de la Vega, L. & de Y\u00e9benes, J. G. Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin. Neuropharmacol. 15, 375\u2013380 (1992).","journal-title":"Clin. Neuropharmacol."},{"key":"681_CR263","doi-asserted-by":"publisher","first-page":"eaau6323","DOI":"10.1126\/science.aau6323","volume":"364","author":"V Maini Rekdal","year":"2019","unstructured":"Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J. & Balskus, E. P. Discovery and inhibition of an interspecies gut bacterial pathway for levodopa metabolism. Science 364, eaau6323 (2019).","journal-title":"Science"},{"key":"681_CR264","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08294-y","volume":"10","author":"SP van Kessel","year":"2019","unstructured":"van Kessel, S. P. et al. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson\u2019s disease. Nat. Commun. 10, 310 (2019).","journal-title":"Nat. Commun."},{"key":"681_CR265","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41582-019-0145-9","volume":"15","author":"P Limousin","year":"2019","unstructured":"Limousin, P. & Foltynie, T. Long-term outcomes of deep brain stimulation in Parkinson disease. Nat. Rev. Neurol. 15, 234\u2013242 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"681_CR266","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1093\/brain\/aws086","volume":"135","author":"E Arai","year":"2012","unstructured":"Arai, E. et al. Subthalamic deep brain stimulation can improve gastric emptying in Parkinson\u2019s disease. Brain 135, 1478\u20131485 (2012).","journal-title":"Brain"},{"key":"681_CR267","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2017-000132","volume":"4","author":"A Su","year":"2017","unstructured":"Su, A., Gandhy, R., Barlow, C. & Triadafilopoulos, G. Utility of the wireless motility capsule and lactulose breath testing in the evaluation of patients with Parkinson\u2019s disease who present with functional gastrointestinal symptoms. BMJ Open Gastroenterol. 4, e000132 (2017).","journal-title":"BMJ Open Gastroenterol."},{"key":"681_CR268","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1111\/jgs.13675","volume":"63","author":"S Shiina","year":"2015","unstructured":"Shiina, S. et al. Levodopa does not worsen gastric emptying in Parkinson\u2019s disease. J. Am. Geriatr. Soc. 63, 2185\u20132186 (2015).","journal-title":"J. Am. Geriatr. Soc."},{"key":"681_CR269","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jocd.2020.07.001","volume":"24","author":"YJ Tan","year":"2020","unstructured":"Tan, Y. J. et al. Osteoporosis in Parkinson\u2019s disease: relevance of distal radius dual-energy X-ray absorptiometry (DXA) and sarcopenia. J. Clin. Densitom. 24, 351\u2013361 (2020).","journal-title":"J. Clin. Densitom."},{"key":"681_CR270","doi-asserted-by":"publisher","DOI":"10.1186\/s40734-016-0036-9","volume":"3","author":"T Virmani","year":"2016","unstructured":"Virmani, T., Tazan, S., Mazzoni, P., Ford, B. & Greene, P. E. Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson\u2019s disease. J. Clin. Mov. Disord. 3, 8 (2016).","journal-title":"J. Clin. Mov. Disord."},{"key":"681_CR271","doi-asserted-by":"publisher","first-page":"eaat9931","DOI":"10.1126\/science.aat9931","volume":"363","author":"M Zimmermann","year":"2019","unstructured":"Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R. & Goodman, A. L. Separating host and microbiome contributions to drug pharmacokinetics and toxicity. Science 363, eaat9931 (2019).","journal-title":"Science"},{"key":"681_CR272","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41586-019-1291-3","volume":"570","author":"M Zimmermann","year":"2019","unstructured":"Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R. & Goodman, A. L. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature 570, 462\u2013467 (2019).","journal-title":"Nature"},{"key":"681_CR273","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.cell.2020.05.001","volume":"181","author":"B Javdan","year":"2020","unstructured":"Javdan, B. et al. Personalized mapping of drug metabolism by the human gut microbiome. Cell 181, 1661\u20131679 (2020).","journal-title":"Cell"},{"key":"681_CR274","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.parkreldis.2018.04.003","volume":"54","author":"JA Vizcarra","year":"2018","unstructured":"Vizcarra, J. A., Wilson-Perez, H. E., Fasano, A. & Espay, A. J. Small intestinal bacterial overgrowth in Parkinson\u2019s disease: tribulations of a trial. Parkinsonism Relat. Disord. 54, 110\u2013112 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"681_CR275","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1474-4422(15)00007-1","volume":"14","author":"A Fasano","year":"2015","unstructured":"Fasano, A., Visanji, N. P., Liu, L. W. C., Lang, A. E. & Pfeiffer, R. F. Gastrointestinal dysfunction in Parkinson\u2019s disease. Lancet Neurol. 14, 625\u2013639 (2015).","journal-title":"Lancet Neurol."},{"key":"681_CR276","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/WNF.0000000000000037","volume":"37","author":"E Narozanska","year":"2014","unstructured":"Narozanska, E. et al. Pharmacokinetics of levodopa in patients with Parkinson disease and motor fluctuations depending on the presence of Helicobacter pylori infection. Clin. Neuropharmacol. 37, 96\u201399 (2014).","journal-title":"Clin. Neuropharmacol."},{"key":"681_CR277","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41575-019-0173-3","volume":"16","author":"ME Sanders","year":"2019","unstructured":"Sanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R. & Rastall, R. A. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat. Rev. Gastroenterol. Hepatol. 16, 605\u2013616 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"681_CR278","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41591-019-0439-x","volume":"25","author":"J Suez","year":"2019","unstructured":"Suez, J., Zmora, N., Segal, E. & Elinav, E. The pros, cons, and many unknowns of probiotics. Nat. Med. 25, 716\u2013729 (2019).","journal-title":"Nat. Med."},{"key":"681_CR279","doi-asserted-by":"publisher","first-page":"eaaw1815","DOI":"10.1126\/scitranslmed.aaw1815","volume":"11","author":"NSE Zmora","year":"2019","unstructured":"Zmora, N. S. E. & Elinav, E. Transforming medicine with the microbiome. Sci. Transl. Med. 11, eaaw1815 (2019).","journal-title":"Sci. Transl. Med."},{"key":"681_CR280","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/jama.2019.19602","volume":"323","author":"CP Harkins","year":"2019","unstructured":"Harkins, C. P., Kong, H. H. & Segre, J. A. Manipulating the human microbiome to manage disease. JAMA 323, 303\u2013304 (2019).","journal-title":"JAMA"},{"key":"681_CR281","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/mds.27390","volume":"33","author":"MCL Phillips","year":"2018","unstructured":"Phillips, M. C. L., Murtagh, D. K. J., Gilbertson, L. J., Asztely, F. J. S. & Lynch, C. D. P. Low-fat versus ketogenic diet in Parkinson\u2019s disease: a pilot randomized controlled trial. Mov. Disord. 33, 1306\u20131314 (2018).","journal-title":"Mov. Disord."},{"key":"681_CR282","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3390\/cells9020376","volume":"9","author":"T Hegelmaier","year":"2020","unstructured":"Hegelmaier, T. et al. Interventional influence of the intestinal microbiome through dietary intervention and bowel cleansing might improve motor symptoms in Parkinson\u2019s disease. Cells 9, 376 (2020).","journal-title":"Cells"},{"key":"681_CR283","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1212\/WNL.0000000000004568","volume":"89","author":"RB Postuma","year":"2017","unstructured":"Postuma, R. B. et al. Caffeine as symptomatic treatment for Parkinson disease (Cafe-PD): a randomized trial. Neurology 89, 1795\u20131803 (2017).","journal-title":"Neurology"},{"key":"681_CR284","doi-asserted-by":"publisher","DOI":"10.1016\/j.gpb.2021.08.009","author":"A Becker","year":"2021","unstructured":"Becker, A. et al. Effects of resistant starch on symptoms, fecal markers and gut microbiota in Parkinson\u2019s disease\u2013the RESISTA-PD trial. Genomics Proteom. Bioinforma. https:\/\/doi.org\/10.1016\/j.gpb.2021.08.009 (2021).","journal-title":"Genomics Proteom. Bioinforma."},{"key":"681_CR285","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1212\/WNL.0000000000003127","volume":"87","author":"M Barichella","year":"2016","unstructured":"Barichella, M. et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: an RCT. Neurology 87, 1274\u20131280 (2016).","journal-title":"Neurology"},{"key":"681_CR286","doi-asserted-by":"crossref","first-page":"e772","DOI":"10.1212\/WNL.0000000000011803","volume":"96","author":"AH Tan","year":"2021","unstructured":"Tan, A. H. et al. Probiotics for constipation in Parkinson disease: a randomized placebo-controlled study. Neurology 96, e772\u2013e782 (2021).","journal-title":"Neurology"},{"key":"681_CR287","doi-asserted-by":"publisher","first-page":"106791","DOI":"10.1016\/j.clineuro.2021.106791","volume":"207","author":"A Segal","year":"2021","unstructured":"Segal, A., Zlotnik, Y., Moyal-Atias, K., Abuhasira, R. & Ifergane, G. Fecal microbiota transplant as a potential treatment for Parkinson\u2019s disease\u2013a case series. Clin. Neurol. Neurosurg. 207, 106791 (2021).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"681_CR288","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12934-021-01589-0","volume":"20","author":"XY Kuai","year":"2021","unstructured":"Kuai, X. Y. et al. Evaluation of fecal microbiota transplantation in Parkinson\u2019s disease patients with constipation. Microb. Cell Fact. 20, 98 (2021).","journal-title":"Microb. Cell Fact."},{"key":"681_CR289","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1053\/j.gastro.2019.07.025","volume":"157","author":"K Aden","year":"2019","unstructured":"Aden, K. et al. Metabolic functions of gut microbes associate with efficacy of tumor necrosis factor antagonists in patients with inflammatory bowel diseases. Gastroenterology 157, 1279\u20131292 (2019).","journal-title":"Gastroenterology"},{"key":"681_CR290","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.prdoa.2019.06.001","volume":"1","author":"RA Hauser","year":"2019","unstructured":"Hauser, R. A. et al. Targeting neurons in the gastrointestinal tract to treat Parkinson\u2019s disease. Clin. Parkinsonism Relat. Disord. 1, 2\u20137 (2019).","journal-title":"Clin. Parkinsonism Relat. Disord."},{"key":"681_CR291","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41575-019-0204-0","volume":"16","author":"SV Lynch","year":"2019","unstructured":"Lynch, S. V., Ng, S. C., Shanahan, F. & Tilg, H. Translating the gut microbiome: ready for the clinic? Nat. Rev. Gastroenterol. Hepatol. 16, 656\u2013661 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00681-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00681-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00681-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T21:07:12Z","timestamp":1668460032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00681-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":291,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["681"],"URL":"https:\/\/doi.org\/10.1038\/s41582-022-00681-2","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,24]]},"assertion":[{"value":"27 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}